RxDoctor Payments Data

Buthena Nagi

Internal Medicine · Warner Robins, GANPI 1255609350

Payments from drug & device makers

$7,647in general payments, 2019–2025

Across 410 payments — averaging $18.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$978
  • Otsuka America Pharmaceutical, Inc.$605
  • AstraZeneca$591
  • Pfizer$477
  • AbbVie$439
  • Amgen$437
  • plus $4K from 39 others

What the payments were for

  • Food & beverage$7,647100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,647 in reported general payments places this provider in the 90th percentile of 3,311 internal medicine providers in Georgia.

See all internal medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$101,249
Medicare patients
224
Services billed
1,666

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol52$62,142
JanuviaSitagliptin Phosphate33$42,006
EliquisApixaban28$32,415
JardianceEmpagliflozin24$32,087
OzempicSemaglutide23$27,395
EntrestoSacubitril/Valsartan23$20,935
MounjaroTirzepatide11$18,253
Breztri AerosphereBudesonide/Glycopyr/Formoterol16$16,779
LinzessLinaclotide14$14,885
TrulicityDulaglutide13$14,581
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$10,614
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen355$7,275
MyrbetriqMirabegron11$6,639
Lantus SolostarInsulin Glargine,hum.Rec.Anlog27$3,484
Venlafaxine Hcl ErVenlafaxine Hcl14$1,545

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Breztri Aerosphere$591$78,92168 claims
MerckJanuvia$110$42,00633 claims
Lilly USA, LLCMounjaro, Trulicity$262$32,83324 claims
PfizerEliquis$477$32,41528 claims
Boehringer IngelheimJardiance$59$32,08724 claims
Novo NordiskOzempic$978$27,39523 claims
NovartisEntresto$73$20,93523 claims
AbbVieLinzess$439$14,88514 claims
GSKTrelegy Ellipta$358$10,61414 claims
Astellas Pharma US IncMyrbetriq$138$6,63911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,311 internal medicine providers in Georgia.

Other internal medicine in Warner Robins

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →